NCT00972686View on ClinicalTrials.gov

Dose-Escalation Study of GSK2126458

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 12, 2012

Study Completion Date

March 31, 2015

Conditions
Solid Tumours
Interventions
DRUG

GSK2126458

GSK2126458 is an experimental treatment for patients with cancer.

Trial Locations (9)

75246

GSK Investigational Site, Dallas

77030

GSK Investigational Site, Houston

94115

GSK Investigational Site, San Francisco

98109

GSK Investigational Site, Seattle

08901

GSK Investigational Site, New Brunswick

27599-7600

GSK Investigational Site, Chapel Hill

84112-5550

GSK Investigational Site, Salt Lake City

1066 CX

GSK Investigational Site, Amsterdam

3584 CX

GSK Investigational Site, Utrecht

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00972686 - Dose-Escalation Study of GSK2126458 | Biotech Hunter | Biotech Hunter